For the quarter ending 2025-09-30, XOMAP has $263,151K in assets. $155,194K in debts. $45,189K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 45,189 | 75,060 | ||
| Short-term restricted cash | 45,288 | 80 | ||
| Investment in equity securities | 1,521 | 8,801 | ||
| Trade and other receivables, net | 3,573 | 1,817 | ||
| Short-term royalty and commercial payment receivables under the eir method | 13,269 | 17,960 | ||
| Short-term royalty and commercial payment receivables under the cost recovery method | 900 | 700 | ||
| Prepaid expenses and other current assets | 967 | 507 | ||
| Total current assets | 110,707 | 104,925 | ||
| Long-term restricted cash | 40,076 | 3,345 | ||
| Property and equipment, net | 24 | 26 | ||
| Operating lease right-of-use assets | 272 | 288 | ||
| Long-term royalty and commercial payment receivables under the eir method | 4,678 | 4,775 | ||
| Long-term royalty and commercial payment receivables under the cost recovery method | 57,864 | 58,937 | ||
| Exarafenib milestone asset (note 6) | 3,500 | 3,402 | ||
| Investment in warrants | 595 | 609 | ||
| Intangible assets, net | 44,556 | 45,434 | ||
| Other assets - long term | 879 | 1,715 | ||
| Total assets | 263,151 | 223,456 | ||
| Accounts payable | 2,654 | 1,138 | ||
| Accrued and other liabilities | 4,134 | 5,411 | ||
| Operating lease liabilities | 2,508 | 472 | ||
| Unearned revenue recognized under units-of-revenue method | 1,320 | 1,434 | ||
| Preferred stock dividend accrual | 1,368 | 1,368 | ||
| Current portion of long-term debt | 14,345 | 11,672 | ||
| Contingent value rights liabilities - current portion | 1,976 | - | ||
| Total current liabilities | 28,305 | 21,495 | ||
| Unearned revenue recognized under units-of-revenue method - long-term | 3,473 | 3,666 | ||
| Exarafenib milestone contingent consideration (note 6) | 3,500 | 3,402 | ||
| Long-term operating lease liabilities | 20,678 | 238 | ||
| Long-term debt | 94,382 | 102,201 | ||
| Contingent value rights liabilities - long-term | 4,807 | - | ||
| Deferred tax liability | 49 | - | ||
| Total liabilities | 155,194 | 131,002 | ||
| Preferred stock-Series BPreferred Stock | - | 0 | ||
| Convertible preferred stock, 0.05 par value, 5,003 shares authorized, issued and outstanding as of september 30, 2025 and december 31, 2024 | 20,019 | 20,019 | ||
| Preferred stock-Series APreferred Stock | 49 | 49 | ||
| Common stock, 0.0075 par value, 277,333,332 shares authorized, 12,310,300 and 11,952,377 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 92 | 90 | ||
| Additional paid-in capital | 1,301,542 | 1,300,066 | ||
| Accumulated other comprehensive income | 121 | 122 | ||
| Accumulated deficit | -1,213,866 | -1,227,892 | ||
| Total stockholders' equity | 87,938 | 72,435 | ||
| Total liabilities, convertible preferred stock and stockholders' equity | 263,151 | 223,456 | ||
XOMA Royalty Corp (XOMAP)
XOMA Royalty Corp (XOMAP)